RALEIGH, N.C., July 17 /PRNewswire/ -- Micell Technologies announces the launch of its new website, providing information on the biomedical applications of the Company’s technology.
Micell Technologies is a privately-held, early-stage biomedical company dedicated to advancing combination product therapies in the cardiovascular, orthopedic, and drug-delivery areas. The Company’s patented processes and methods for medical device surface modification using supercritical fluids are focused on improvements to current polymer based drug-eluting technologies.
The Company’s strong intellectual property portfolio consists of issued U.S. and International patents covering a variety of applications of supercritical fluids. Included in the technology platform are exclusively licensed patents from Pacific Northwest National Laboratory, a U.S. Department of Energy laboratory, managed by Battelle. Micell is continuing to innovate, and complements its patent portfolio with an important body of proprietary supercritical fluid expertise.
In addition to its intellectual property portfolio, Micell has an experienced and accomplished team with significant business and supercritical fluid experience. Management includes Arthur J. Benvenuto, Chairman and Chief Executive Officer, James B. McClain, Ph.D., Chief Technology Officer and Jonathan E. Kennedy, Chief Financial Officer.
To learn more, please visit our new website at www.micell.com
Micell Technologies
CONTACT: James McClain, Chief Technology Officer of Micell Technologies,+1-919-313-2111
Web site: http://www.micell.com/
